BETA
Your AI-Trained Oncology Knowledge Connection!
Jordyn Sava is an editor for Targeted Oncology.
Dr Voorhees on CARTITUDE-1: Cilta-Cel Sets New Bar in Myeloma Survival
Dr Srour Presents Promising Phase 1 Results for ALLO-316 in ccRCC
ALLO-316 shows promising results in advanced renal cell carcinoma, with a 25% response rate and rapid treatment turnaround, paving the way for future studies.
FDA Approves SIR-Spheres Y-90 for First-Line Use in Unresectable HCC
The FDA approves SIR-Spheres Y-90 microspheres for treating unresectable hepatocellular carcinoma, showcasing impressive efficacy and safety in clinical trials.
FDA Clears Oncomine Dx Express Test for Sunvozertinib in EGFR Exon 20+ NSCLC
The FDA approves a rapid test for identifying patients with NSCLC eligible for sunvozertinib, enhancing timely, precision oncology care.
Luspatercept’s Benefit in MDS: Dr Garcia-Manero on COMMANDS Trial
Luspatercept-aamt shows significant survival benefits and transfusion independence in lower-risk MDS, reshaping treatment standards in hematology.
Dr Hankins Investigates Erectile Dysfunction Risk After Prostate Cancer Radiation
A new study reveals that rectal spacers during prostate cancer radiation therapy significantly reduce long-term erectile dysfunction rates, enhancing patient outcomes.
Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma
Long-Term Data Validates IsoPSA for Prostate Cancer Risk Stratification
Dr Klempner Highlights Practice-Changing Role of Durvalumab/FLOT in Gastric Cancer
Durvalumab enhances event-free survival in resectable gastric and gastroesophageal cancers, revolutionizing neoadjuvant therapy according to the MATTERHORN trial.
FDA Greenlights Linvoseltamab in Relapsed/Refractory Multiple Myeloma
Linvoseltamab represents a promising new approach to treating multiple myeloma through immune-based therapy.
Dr Salhotra Details Orca-T’s Performance in Phase 3 Precision-T Trial
Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.
QUILT-88 Study: Promising Survival in Pancreatic Cancer
The QUILT-88 study reveals promising survival rates for advanced pancreatic cancer patients using a multimodal treatment approach, combining chemotherapy and immunotherapy.
TYRA-300 Begins Phase 2 Trial in FGFR3-Altered NMIBC
A groundbreaking trial for TYRA-300, an oral FGFR3 inhibitor, aims to transform treatment for patients with low-grade intermediate-risk bladder cancer.
Daraxonrasib Earns FDA Breakthrough Status in Pancreatic Cancer
Daraxonrasib gains FDA breakthrough therapy status for treating metastatic pancreatic cancer with KRAS G12X mutations, showing promising survival rates.
Bemarituzumab Plus Chemo Improves OS in FGFR2b+ Gastric Cancer
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options.
Boosting Oncology Trials: LLM Accuracy Meets Unprecedented Speed
AI streamlines patient identification for clinical trials, significantly reducing review time while maintaining high accuracy, transforming oncology workflows.
Oncologists’ Guide to the FDA Approval of Tafasitamab for Relapsed FL
FDA approves tafasitamab with lenalidomide and rituximab, offering a groundbreaking chemotherapy-free treatment for relapsed follicular lymphoma.
FDA Approves Updated Labels on CAR T-Cell Therapies, Eliminating REMS
FDA updates CAR T-cell therapy labels, easing monitoring requirements and expanding access for eligible patients in oncology.
FDA Grants RMAT Designation for Detalimogene in NMIBC
Detalimogene voraplasmid gains FDA RMAT designation, showcasing a 71% response rate in treating high-risk, BCG-unresponsive NMIBC with promising safety.
CAR T Trial for Recurrent Ovarian Cancer Advances to 4th Cohort
Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy in ongoing clinical trials.
Dr Leleu on SC Isatuximab via On-Body Injector in R/R Multiple Myeloma
Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment efficiency in the IRAKLIA study.
FDA Grants Accelerated Approval to Dato-DXd in Previously Treated EGFR+ NSCLC
FDA accelerates approval of datopotamab deruxtecan for advanced EGFR-mutated NSCLC, offering new hope for previously treated patients.
Hochhaus on ASC4START and Asciminib’s Superior Tolerability in CML-CP
FDA Clears IND for Phase 1 Study of Lonitoclax in Relapsed/Refractory AML
FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies.
Selinexor Shows Promise for Enhancing CAR T Outcomes in Myeloma
FDA Grants Orphan Drug Designation to SENTI-202 for R/R AML
SENTI-202, a groundbreaking CAR NK-cell therapy, targets relapsed/refractory AML, offering hope for patients with limited treatment options.
Dr Loong on Sevabertinib in HER2-Mutant NSCLC: SOHO-01 Trial Insights
Sevabertinib shows promise as a targeted therapy for HER2-mutant non-small cell lung cancer, addressing significant treatment gaps in this area.
FDA Approves Tafasitamab in R/R Follicular Lymphoma
Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.
Atebimetinib Combination Shows Promising Survival Data in Pancreatic Cancer
New trial data reveals atebimetinib combined with gemcitabine/nab-paclitaxel significantly improves survival rates in pancreatic cancer patients.
FDA Approves Label Update But Not Expansion for Talazoparib/Enzalutamide in mCRPC
FDA updates talazoparib and enzalutamide labeling, confirming survival benefits for HRR-mutated mCRPC, while excluding non-HRR patients.